5am Ventures is an SEC-registered investment adviser based in San Francisco, CA that reports managing 1 hedge fund on Form ADV. It reports $1.1 billion in regulatory assets under management. Its private funds, of all types, hold $947.0 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +48.0% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +70.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $1.1 billionForm ADV Item 5.F
- Gross assets of private funds
- $947.0 millionAll private fund types, Form ADV
- Hedge funds managed
- 112 private funds in total
- Employees
- 32Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 160395
- Latest Form ADV
- 03/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +11.2% | +14.8% |
| Q1 2026 | +33.1% | -4.6% |
| Q4 2025 | +26.9% | +2.4% |
| Q3 2025 | +34.5% | +7.8% |
| Q2 2025 | +7.0% | +10.4% |
| Q1 2025 | -33.1% | -4.5% |
| Q4 2024 | -11.2% | +2.1% |
| Q3 2024 | +6.2% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- 56565p103$34.0 million
- Tyra Biosciences Inc$32.9 million
- Entrada Therapeutics Inc$29.9 million
- Pharvaris N V$27.6 million
- Camp4 Therapeutics Corp$25.6 million
- Artiva Biotherapeutics Inc$22.8 million
- Tectonic Therapeutic Inc$20.9 million
- Zentalis Pharmaceuticals Inc$19.1 million
- Celldex Therapeutics Inc New Com New$18.5 million
- Eyepoint Pharmaceuticals Inc$15.0 million
As of 2026-06-30, from 13F filing by 5AM Venture Management, LLC.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures